Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cuizhen Niu

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Biostatistics (Oxford, England)|August 31, 2018
Letter to the editorXu Guo, Yujing Gao, Cuizhen Niu, et al.
Journal of Biopharmaceutical Statistics|June 6, 2024
Application of estimand framework to the design and analysis of multi-regional clinical trialsCuizhen Niu, Liwen Liang, Rong Fu, et al.
Future Oncology (London, England)|January 27, 2023
KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancerChristian Gratzke, Mariusz Kwiatkowski, Ugo De Giorgi, et al.
Frontiers in Immunology|October 28, 2022
Pembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 studyLu Si, Xiaoshi Zhang, Yongqian Shu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 2, 2021
Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing SchedulesGeorgina V Long, Caroline Robert, Marcus O Butler, et al.
Prostate Cancer and Prostatic Diseases|August 12, 2024
Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 studyJulie N Graff, Christopher J Hoimes, Winald R Gerritsen, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Biostatistics (Oxford, England)|August 31, 2018
Letter to the editorXu Guo, Yujing Gao, Cuizhen Niu, et al.
Journal of Biopharmaceutical Statistics|June 6, 2024
Application of estimand framework to the design and analysis of multi-regional clinical trialsCuizhen Niu, Liwen Liang, Rong Fu, et al.
Future Oncology (London, England)|January 27, 2023
KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancerChristian Gratzke, Mariusz Kwiatkowski, Ugo De Giorgi, et al.
Frontiers in Immunology|October 28, 2022
Pembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 studyLu Si, Xiaoshi Zhang, Yongqian Shu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 2, 2021
Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing SchedulesGeorgina V Long, Caroline Robert, Marcus O Butler, et al.
Prostate Cancer and Prostatic Diseases|August 12, 2024
Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 studyJulie N Graff, Christopher J Hoimes, Winald R Gerritsen, et al.
Pageof 1